Acetic Acid 2% Solution for Skin Ulcers

Launched by CONSORCI SANITARI DE L'ALT PENEDÈS I GARRAF · Feb 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a 2% acetic acid solution for treating chronic skin ulcers that have biofilm, which is a layer of bacteria that can make healing difficult. The main goal is to see if this new treatment works better than the current standard treatment, which is a product called Prontosan®. Participants will be randomly assigned to receive either the acetic acid treatment or the standard treatment to compare their effects.

To be eligible for the study, participants need to be at least 18 years old and have a specific type of skin ulcer that is less than 120 cm² in size. They must also be able to receive care at a designated health center and commit to follow-up visits for at least 8 weeks. It's important to note that individuals with certain conditions, such as ulcers with exposed bone or those lasting more than 18 months, cannot participate. If you join the study, you will receive either the new treatment or the standard one, and you'll be monitored closely to see how well your ulcer heals. This trial is not yet recruiting participants, but it represents an important step in finding better ways to treat difficult skin ulcers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age.
• • Continued care (hospital or outpatient) in one of the Consorci Sanitari Alt Penedes i Garraf (CSAPG) units.
• • Presence of a cutaneous ulcer with biofilm, with an area of less than 120 cm2, and in any location (except the facial region).
• • Plan to undergo treatment and follow-up of the lesion (at least 8 weeks) at the study center.
• • Ability to cooperate in necessary evaluations.
• • Informed consent for inclusion in the study, either from the participant themselves or from their legal representative.
• Exclusion Criteria:
• * Participants diagnosed with any of the following conditions:
• • 1. Ulcers with exposed bone tissue.
• • 2. Neoplastic-origin ulcers.
• • 3. Ulcers lasting more than 18 months.
• • Participation in another clinical trial involving an experimental intervention during the period of the current trial and/or establishing a visit frequency incompatible with the current trial.